Early in the COVID-19 pandemic, there was concern in the media that the use of non-
steroidal antiinflammatory drugs (NSAIDs), particularly ibuprofen, might exacerbate COVID …

We read with interest the studies by Renaud Felten and colleagues1 and Laura Boekel and
colleagues2 published in The Lancet Rheumatology, which both contribute essential …

Comment e676 www. thelancet. com/rheumatology Vol 3 October 2021 8375 [90· 1%]
women and 893 [9· 6%] men) between April 3 and May 8, 2020. The most frequent …

There is a continuous debate about the risks of increased incidence of COVID-19 in
vulnerable patient groups, which includes patients with rheumatic diseases and especially …

Although viruses can induce rheumatic diseases, the impact of SARS-CoV-2, the virus
behind COVID-19, on the development of systemic rheumatic disease is unclear. COVID-19 …

The pattern and mechanism of inflammation in COVID-19 remains unclear, although
multiple cytokines are elevated in severe infection. 1 An early report found that some …

We read the Article by Thomas Huet and colleagues1 describing the effects of the
interleukin1 receptor antag onist anakinra in patients with severe COVID19 with great …

The COVID-19 pandemic is ongoing, and the SARS-CoV-2 delta variant has resulted in
disease resurgence. As many as 20% of people infected with SARS-CoV-2 suffer from …

The current outbreak of COVID19, caused by severe acute respiratory syndrome
coronavirus 2 (SARSCoV2), is characterised by clinical signs and symptoms such as …

1 Boekel L, Atiqi S, Leeuw M, et al. Post-COVID condition in patients with inflammatory
rheumatic diseases: a prospective cohort study in the Netherlands. Lancet Rheumatol 2023; …